RegeneRx Biopharmaceuticals, Inc. engages in the development of a novel therapeutic peptide, Thymosin beta 4 for tissue and organ protection, repair, and regeneration. Its product pipeline includes RGN-259, RGN-352, and RGN-137. The company was founded by Allan L. Goldstein on May 13, 1982 and is headquartered in Rockville, MD.